The company is launching a new clinically-backed Pantene hair care system targeting hair loss, sparking fresh investor interest. It is relying on major product upgrades while maintaining flat margins to balance stability with growth amid soft demand. The company is lagging behind the consumer defensive sector, with shares closing at $146.98 and a negative one-year shareholder return. Leadership will present at an upcoming Morgan Stanley conference. The company recently challenged a competitor's social media advertising practices, resulting in modified disclosures.